According to an article in The Sunday Times in the UK over the weekend, a well-known surgeon in the UK is claiming to have carried out “the first” radical prostatectomy on a man with no other indicator for treatment except a BRCA2 mutation and a significant family history of breast and prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: BRCA1, BRCA2, prophylactic, risk, surgery, Treatment | 5 Comments »
Apparently a drug known as olaparib (a so-called poly-ADP ribose polymerase or PARP inhibitor) has shown significant signs of activity against advanced prostate cancer in men who carry the BRCA1 and BRCA2 genes. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, BRCA1, BRCA2, olaparib | 2 Comments »
A new study just published on line in the Journal of Clinical Oncology had confirmed that “BRCA1/2 mutations confer a more aggressive [prostate cancer] phenotype with a higher probability of nodal involvement and distant metastasis.” This is not a surprising finding, but it does have real implications for men with a family history of BRCA1/2 mutations. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: BRCA1, BRCA2, hereditary, mortality, risk, survival | 8 Comments »
According to another Reuters report, men who develop prostate cancer and who carry one of three possible hereditary mutations to the so-called breast cancer genes BRCA1 and BRCA2 appear to be at particularly high risk for an aggressive form of the disease. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressive disease, BRCA1, BRCA2, mutation, risk | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 